- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02089048
Auranofin PK Following Oral Dose Administration
An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66211-1553
- Quintiles Phase I Services - Overland Park
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-Personally signed and dated informed consent document. -Healthy male or female of non-childbearing potential, between the ages of 18 and 45 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including vital signs, and clinical laboratory tests. Non-childbearing potential is defined as amenorrheic for at least 2 years plus a serum follicle-stimulating hormone (FSH) level > 30 IU/L, or documented bilateral oophorectomy and/or hysterectomy, or tubal ligation. -Body mass index (BMI) of 18 to 30 [weight (kg)]/ [height (m)^2] inclusive; and a total body weight > 50 kg (110 lbs) and < 122 kg (250 lbs) at the Screening Visit. -Male subjects willing to use appropriate contraception for the duration of the study. -Willing and able to comply with scheduled visits, dosing plan, laboratory tests, and other study procedures.
Exclusion Criteria:
-Evidence or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, musculoskeletal, immunologic, neurologic or dermatologic disease (including drug allergies that are clinically significant) which in the opinion of the Investigator could impact the participation of the subject in the study or the assessment of the study endpoints. -Current evidence of or history of malignancy (excepting completely treated cervical cancer in situ or intraductal carcinoma of the breast, or </= 2 basal cell and/or squamous cell carcinomas of the skin completely excised) in the 5 years prior to Day -1 with no evidence of recurrence. -Breastfeeding or a positive serum pregnancy test at the Screening Visit or Day -1. -History of drug abuse within 6 months prior to study drug administration. -A history of alcohol abuse, defined as regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor), within 6 months prior to study drug administration. -Positive results from a standard urine drug screen (Screening Visit or Day -1) or a positive test for alcohol (Screening visit or Day -1). -Daily use of tobacco- or nicotine-containing products (cigarettes, pipe, cigar, chewing tobacco or nicotine gum, lozenges or patches). Occasional social smoking is acceptable. You must not change your use of tobacco from your first visit and through completion of the last visit of the study. -Treatment with an investigational drug within 30 days prior to study drug administration. -Prior exposure to gold-containing products. -Use of any prescription or nonprescription drugs, vitamins, or dietary or herbal supplements within 14 days prior to study drug administration. As exceptions, acetaminophen may be used at doses of </=1 g/day until 24 hours prior to study drug administration. -Blood donation of >/= 1 pint (473 mL) within 30 days prior to study drug administration. -Plasma and platelet donation within 14 days prior to study drug administration. -Screening liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) greater than upper limit of normal (ULN). -Evidence of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection upon serological testing at the Screening Visit. -Evidence of active infection or febrile illness (e.g., bronchopulmonary, urinary or gastrointestinal) within 7 days prior to study drug administration. -History of allergy to auranofin or any of the excipients in the capsules. (excipients per the package insert of auranofin are listed in Section 6.1) -Any other condition that, in the opinion of the investigator, poses a risk to the safety of the individual or the valid conduct of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
15 subjects receive 6mg of auranofin once every 24 hours for 7 days
|
Auranofin is a gold-containing chemical salt available as 3mg capsules.
Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentrations of gold following 7 once daily doses of auranofin
Time Frame: Up to Day 126
|
Up to Day 126
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Type, frequency and severity of Serious AEs (SAEs) to the end of study
Time Frame: Up to Day 126
|
Up to Day 126
|
Type, frequency and severity of treatment-emergent adverse events (TEAEs) to 14 days after administration of the first dose
Time Frame: 14 Days after first dose
|
14 Days after first dose
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-0101
- HHSN272200800024C
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amoebiasis
-
Janssen-Cilag Ltd.Completed
-
Swiss Tropical & Public Health InstituteInstitute of Tropical Medicine, Belgium; B.P. Koirala Institute of Health Sciences and other collaboratorsCompletedShigellosis | Schistosomiasis | Strongyloidiasis | Dientamoebiasis | Giardiasis | Amoebiasis | Soil-transmitted Helminthiasis | Intestinal Salmonellosis | Campylobacteriosis | Aeromonas Spp. Infections | Cryptosporidium Spp. InfectionsCôte D'Ivoire, Indonesia, Mali, Nepal
Clinical Trials on Auranofin
-
University of Kansas Medical CenterThe Leukemia and Lymphoma Society; Kansas Bioscience Authority; Therapeutics...CompletedLeukemia, Prolymphocytic | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic LymphomaUnited States
-
Mayo ClinicCompletedRecurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Vaccine and Gene Therapy Institute, FloridaUniversity of MiamiWithdrawn
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnUnspecified Adult Solid Tumor, Protocol Specific | Recurrent Non-small Cell Lung CancerUnited States
-
Swiss Paraplegic Centre NottwilCompletedMild Cognitive Impairment | Spinal Cord InjuriesSwitzerland
-
University of Sao PauloUnknownCarcinoma, Basal CellBrazil
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRecurrent Ovarian Carcinoma | Ovarian Serous TumorUnited States